Stockreport

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Redhill Biopharma Ltd. - American Depositary Shares  (RDHL) 
US:NASDAQ Investor Relations: ir.redhillbio.com/investor-relations
PDF Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mor [Read more]